Distinct Progression and Efficacy of First-Line Osimertinib Treatment According to Mutation Subtypes in Metastatic NSCLC Harboring EGFR Mutations
- Resource Type
- Article
- Source
- In
JTO Clinical and Research Reports February 2024 5(2) - Subject
- Language
- ISSN
- 2666-3643